SCHEMBL7602374

SCHEMBL7602374

Fc1ccc(-c2c3ccccc3c(-c3ccc(-n4c5ccccc5c5ccccc54)cc3)c3ccccc23)cc1F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 4/20 0.47
KDM4E B2RXH2 1/20 0.47
ATM Q13315 1/20 0.47
KMT2A Q03164 3/20 0.37
HDAC4 P56524 1/20 0.36
MEN1 O00255 2/20 0.36
CYP1A2 P05177 2/20 0.36
USP2 O75604 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
EDNRA P25101 3/20 0.34
EDNRB P24530 1/20 0.34
USP14 P54578 1/20 0.34
IL1R1 P14778 1/20 0.34
ALDH1A1 P00352 1/20 0.33
MAPT P10636 1/20 0.33
HTT P42858 1/20 0.33
JAK2 O60674 1/20 0.33
JAK3 P52333 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7601614 0.87 L3MBTL1 (0.43) L3MBTL1KDM4EATMKMT2AHDAC4
SCHEMBL275300 0.85 L3MBTL1 (0.64) L3MBTL1KDM4EATMKMT2AHDAC4
SCHEMBL12571778 0.83 L3MBTL1 (0.53) L3MBTL1KDM4EATMKMT2AHDAC4
SCHEMBL7605400 0.83 KDM4E (0.53) L3MBTL1KDM4EATMKMT2AHDAC4
SCHEMBL7601633 0.83 CNR2 (0.43) L3MBTL1KDM4EATMKMT2AHDAC4
SCHEMBL7601620 0.83 CYP11B1 (0.45) L3MBTL1KDM4EATM
SCHEMBL7605415 0.83 KDM4E (0.46) L3MBTL1KDM4EATMKMT2AHDAC4
SCHEMBL14211434 0.83 L3MBTL1 (0.61) L3MBTL1KDM4EATMKMT2AHDAC4
SCHEMBL13592779 0.83 L3MBTL1 (0.61) L3MBTL1KDM4EATMKMT2AHDAC4
SCHEMBL7605425 0.83 L3MBTL1 (0.48) L3MBTL1KDM4EATMKMT2AHDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8183793-B2 Method for synthesizing anthracene derivative and anthracene derivative, light emitting element, light emitting device, electronic device SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2012-05-22 US disclosed
US-8183793-B2 Method for synthesizing anthracene derivative and anthracene derivative, light emitting element, light emitting device, electronic device SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2012-05-22 US disclosed
US-20110050118-A1 METHOD FOR SYNTHESIZING ANTHRACENE DERIVATIVE AND ANTHRACENE DERIVATIVE, LIGHT EMITTING ELEMENT, LIGHT EMITTING DEVICE, ELECTRONIC DEVICE SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2011-03-03 US disclosed
US-20110050118-A1 METHOD FOR SYNTHESIZING ANTHRACENE DERIVATIVE AND ANTHRACENE DERIVATIVE, LIGHT EMITTING ELEMENT, LIGHT EMITTING DEVICE, ELECTRONIC DEVICE SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2011-03-03 US disclosed
US-20080107918-A1 METHOD FOR SYNTHESIZING ANTHRACENE DERIVATIVE AND ANTHRACENE DERIVATIVE, LIGHT EMITTING ELEMENT, LIGHT EMITTING DEVICE, ELECTRONIC DEVICE SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2008-05-08 US disclosed
US-20080107918-A1 METHOD FOR SYNTHESIZING ANTHRACENE DERIVATIVE AND ANTHRACENE DERIVATIVE, LIGHT EMITTING ELEMENT, LIGHT EMITTING DEVICE, ELECTRONIC DEVICE SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2008-05-08 US disclosed
WO-2008026614-A1 METHOD FOR SYNTHESIZING ANTHRACENE DERIVATIVE AND ANTHRACENE DERIVATIVE, LIGHT EMITTING ELEMENT, LIGHT EMITTING DEVICE, ELECTRONIC DEVICE SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2008-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110050118-A1 METHOD FOR SYNTHESIZING ANTHRACENE DERIVATIVE AND ANTHRACENE DERIVATIVE, LIGHT EMITTING ELEMENT, LIGHT EMITTING DEVICE, ELECTRONIC DEVICE ALAD, CYP2C9, CYP1A1 L3MBTL1 3456/4885KDM4E 2175/4885ATM 527/4885
US-20080107918-A1 METHOD FOR SYNTHESIZING ANTHRACENE DERIVATIVE AND ANTHRACENE DERIVATIVE, LIGHT EMITTING ELEMENT, LIGHT EMITTING DEVICE, ELECTRONIC DEVICE ALAD, CYP2C9, CYP1A1 L3MBTL1 3456/4885KDM4E 2175/4885ATM 527/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.